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Ebola vaccines: an uncertain future?
On Jan 28, the preliminary phase 1 safety data for 
GlaxoSmithKline’s (GSK’s) candidate Ebola vaccine 
were published. The chimpanzee adenovirus vector 
(ChAd3) vaccine, which encodes a wild-type surface 
glycoprotein from Zaire Ebolavirus, raised no safety 
concerns in the 60 healthy volunteers from the UK 
tested and showed reasonable immunogenicity. Five 
days later, the ﬁ rst dose was given to a Liberian man as 
part of an expedited phase 3 trial in west Africa. Phase 
1 trials of at least two other candidates are in progress: 
Merck’s Zaire-strain-encoding vesicular stomatitis virus 
(VSV) vector, and Johnson & Johnson’s heterologous 
prime-boost vaccine based on human Ad26 and 
modiﬁ ed vaccinia Ankara (MVA) vectors expressing 
Zaire strain glycoprotein. 
The rapid roll-out of these trials has been 
tremendously impressive. Yet none of the vaccines 
were originally developed with African public health 
in mind: they were created out of fear that the virus 
could be used as a bioweapon. Concerns over limited 
market size and recipient governments’ ability to pay 
meant that the business case for a population-level 
Ebola vaccine was ﬂ imsy. Now, as the epidemic wanes 
and phase 3 trials and licensing become more complex, 
there is a risk that manufacturers will revert back to this 
previous state of thinking. Declining case numbers have 
already led drug manufacturer Chimerix to pull out of a 
trial of brincidofovir in Liberia. This is disheartening to 
say the least.
The reduction in incidence of Ebola virus disease has 
been brought about by means of a combination of 
scaled-up treatment capacity, safe burial practices, and 
rigorous case and contact ﬁ nding. Vital communication 
and consultation work with communities has 
improved trust and understanding. But, as Brian 
McCloskey from the Oﬃ  ce of the UN Special Envoy on 
Ebola was at pains to point out at a seminar in London 
last week, the outbreak cannot yet be considered 
under control. In fact a slight uptick in cases since the 
beginning of February illustrates his point. He further 
emphasised that the outlook is now not one of a single 
epidemic across three countries, but of perhaps 60 or 
more localised outbreaks with the very real potential to 
spread across borders into countries such as Mali and 
Côte d’Ivoire.
The UN’s response strategy is now moving away from 
a concentration on treating the vast volume of cases and 
towards elimination of transmission. Here vaccines play 
a vital role. It was ring vaccination—ie, the vaccination of 
a “ring” of individuals potentially exposed to a case—that 
saw the eradication of smallpox in 1980. Furthermore, as 
Peter Piot noted at the same seminar, Ebola’s ability to 
disrupt the whole health system by means of decimating 
the workforce is as potent a threat as its case–fatality 
rate. Vaccination of health workers could neutralise this 
threat. With the UN’s focus now on case and contact 
ﬁ nding and with a still-uncertain epidemic trajectory, 
the drive to bring vaccines (and the more the better) to 
licensing and production should not falter.
So what of the realities of this for vaccine 
manufacturers? There is hope. First, a willingness to 
collaborate between governments, funding bodies, 
and companies has been key to the success of the 
vaccine trials so far. The phase 1 GSK vaccine trial in the 
UK, for example, was funded by the Wellcome Trust, 
the UK Department for International Development, 
the UK Medical Research Council, and the UK National 
Institute for Health Research. Financial support for its 
further development is being provided by the European 
Union, the Bill & Melinda Gates Foundation, and the 
Swiss Government. GSK has committed to scaling 
up vaccine production even as later-phase trials are 
ongoing. Second, governments are oﬀ ering levers such 
as tax incentives and extended exclusivity rights to drive 
manufacturers on. And third, regulators are showing 
signs of ﬂ exibility in terms of accelerated licensure in 
the event that the waning epidemic delays the ability to 
demonstrate eﬃ  cacy.
Vaccines are not a magic bullet. Nothing can replace 
the basic tenets of public health epidemiology and 
community mobilisation. But in the early days of a 
new outbreak in an unprepared population, as in all 
likelihood will happen again, vaccines can be a vital 
early weapon. Once we are reasonably assured of safety 
and eﬃ  cacy, everything must be done to ensure that 
stockpiles are ready and the necessary clearances for 
their use are in place.
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